Question 1

What is Revolution Medicines's P/B ratio?

Accepted Answer

Revolution Medicines (RVMD) P/B ratio is 19.7× as of June 5, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for Revolution Medicines?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For Revolution Medicines specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Revolution Medicines's P/B ratio high or low?

Accepted Answer

Revolution Medicines's P/B ratio of 19.7× is above its own 5-year average of 4.1× and above the sector median of 3.4×. That places the current reading at the 99th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Revolution Medicines's historical P/B ratio range?

Accepted Answer

In the available daily series, Revolution Medicines (RVMD) P/B ratio has ranged from a low of 1.7× in 2020 to a high of 21.6× in 2026. The 5-year average is 4.1× and the 5-year median is 3.2×.

Question 7

What was Revolution Medicines's P/B ratio in 2025?

Accepted Answer

Revolution Medicines (RVMD) P/B ratio at the end of 2025 was 9.3×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does Revolution Medicines's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$15.14B	$1.63B	9.3×	+6.0×	Dec 31, 2025
2024	$7.34B	$2.27B	3.2×	+1.0×	Dec 31, 2024
2023	$4.05B	$1.83B	2.2×	-0.9×	Dec 31, 2023
2022	$2.12B	$685.19M	3.1×	+0.0×	Dec 31, 2022
2021	$1.86B	$602.57M	3.1×	-2.4×	Dec 31, 2021
2020	$2.63B	$474.68M	5.5×	-1.4×	Dec 31, 2020
2019	$1.05B	$152.53M	6.9×	—	Dec 31, 2019


Quest Diagnostics (DGX)	2.9×
Moderna (MRNA)	2.7×
Charles River (CRL)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Danaher (DHR)	2.4×
UnitedHealth Group (UNH)	2.4×
Solventum (SOLV)	2.3×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Molina Healthcare (MOH)	1.7×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Elevance Health (ELV)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Revvity (RVTY)	1.4×
Zimmer Biomet Holdings (ZBH)	1.2×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Centene (CNC)	0.8×

P/B Ratio for Revolution Medicines (RVMD)

P/B Ratio daily chart for Revolution Medicines (RVMD)

Historical P/B Ratio for Revolution Medicines (RVMD) from 2019 to 2025

About P/B Ratio at Revolution Medicines (RVMD)

Revolution Medicines P/B Ratio by Year

Revolution Medicines P/B Ratio 2025: 9.3×

Revolution Medicines P/B Ratio 2024: 3.2×

Revolution Medicines P/B Ratio 2023: 2.2×

Revolution Medicines P/B Ratio 2022: 3.1×

Revolution Medicines P/B Ratio 2021: 3.1×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

Revolution Medicines (RVMD) Key Financials

P/B Ratio daily chart for Revolution Medicines (RVMD)

Historical P/B Ratio for Revolution Medicines (RVMD) from 2019 to 2025

About P/B Ratio at Revolution Medicines (RVMD)

Revolution Medicines P/B Ratio by Year

Revolution Medicines P/B Ratio 2025: 9.3×

Revolution Medicines P/B Ratio 2024: 3.2×

Revolution Medicines P/B Ratio 2023: 2.2×

Revolution Medicines P/B Ratio 2022: 3.1×

Revolution Medicines P/B Ratio 2021: 3.1×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

+What is Revolution Medicines's P/B ratio?

+How is the P/B ratio calculated?

+What is the P/B ratio?

+What is a good P/B ratio for Revolution Medicines?

+Is Revolution Medicines's P/B ratio high or low?

+What is Revolution Medicines's historical P/B ratio range?

+What was Revolution Medicines's P/B ratio in 2025?

+Why does Revolution Medicines's P/B ratio change over time?

Revolution Medicines (RVMD) Key Financials